作者: Andrew M. Prentice , Liandré van der Merwe
DOI: 10.1111/J.1740-8709.2011.00313.X
关键词: Immunology 、 Polyunsaturated fatty acid 、 Bioinformatics 、 Clinical trial 、 Medicine 、 Disease 、 Randomized controlled trial 、 Fatty acid 、 Inflammatory bowel disease 、 Environmental enteropathy 、 Population
摘要: In vitro and animal studies point to numerous mechanisms by which fatty acids, especially long-chain polyunsaturated acids (LCPUFA), can modulate the innate adaptive arms of immune system. These data strongly suggest that improving acid supply young children in low-income countries might have benefits. Unfortunately, there been virtually no acid/immune interactions such settings. Clinical trial registers list over 150 randomized controlled trials (RCTs) involving PUFAs, only one a setting (the Gambia). We summarize those results here. There was evidence for improved growth nutritional status, but primary end chronic environmental enteropathy showed benefit, possibly because infants were still substantially breastfed. high-income settings, RCTs with (usually LCPUFAs) relation 18 disease points, some (asthma, inflammatory bowel rheumatoid arthritis). For these diseases, is judged reasonable risk reduction childhood asthma (but not adults), as yielding possible benefit Crohn's (insufficient ulcerative colitis) convincing arthritis at sufficient dose levels, though formal meta-analyses are yet available. This analysis suggests interventions could yield benefits poor non-breastfed conditions persistent enteropathy. Benefits include responses enteric vaccines, frequently perform poorly questions merit trials.